Ivarmacitinib治疗中重度特应性皮炎52周III期试验
这项多中心双盲III期试验纳入336例12-75岁中重度特应性皮炎患者,随机接受ivarmacitinib 4mg、8mg或安慰剂16周,随后双盲延伸至52周。初始ivarmacitinib组第52周IGA应答率42.3%和40.2%,EASI-75应答率60.6%和55.9%,WI-NRS应答率59.6%和45.1%,安全性总体与安慰剂对照期一致。
要点
- ivarmacitinib 4mg和8mg组第52周IGA应答率分别为42.3%和40.2%。
- EASI-75应答率分别为60.6%和55.9%,WI-NRS应答率分别为59.6%和45.1%。
- 52周安全性总体与16周一致,常见上呼吸道感染和血肌酸磷酸激酶升高。
核心结论
- Ivarmacitinib在第52周总体维持改善,安全性特征与安慰剂对照期基本一致。
- 因第16周后无安慰剂对照,长期疗效结果应视为描述性。
研究设计与样本
- 多中心、双盲、III期试验(NCT04875169),纳入336例12-75岁中重度特应性皮炎患者。
- 患者1:1:1随机接受每日一次口服ivarmacitinib 4mg、8mg或安慰剂16周,随后36周双盲延伸。
- 第16周时继续研究的安慰剂组患者重新随机分配至ivarmacitinib 4mg或8mg。
- 258例患者完成52周治疗。
主要发现
- 初始ivarmacitinib组第52周IGA应答率:4mg组42.3%,8mg组40.2%。
- 第52周EASI-75应答率:4mg组60.6%,8mg组55.9%。
- 第52周WI-NRS应答率:4mg组59.6%,8mg组45.1%。
- 活动治疗期TEAE发生率:4mg组87.5%,8mg组85.5%。
- 严重TEAE发生率:4mg组5.6%,8mg组4.4%。
关键数值与推荐
- 第52周关键终点包括IGA 0/1且至少改善2级、EASI-75和WI-NRS应答。
- 最常见TEAE为上呼吸道感染、COVID-19、SARS-CoV-2检测阳性及血肌酸磷酸激酶升高。
临床怎么用
- Ivarmacitinib每日一次口服在中重度特应性皮炎患者中第52周维持皮肤和瘙痒改善。
- 长期用药需关注上呼吸道感染、COVID-19及血肌酸磷酸激酶升高等不良事件。
局限性
- 延伸期第16周后无安慰剂对照,长期疗效发现应解释为描述性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentre, double-blind, phase 3 trial (NCT04875169), patients aged 12-75 years were randomized 1:1:1 to receive once-daily oral ivarmacitinib 4 mg, ivarmacitinib 8 mg, or placebo for 16 weeks, followed by a 36-week double-blind extension. At Week 16, placebo-treated patients who continued in the study were re-randomized to ivarmacitinib 4 mg or 8 mg. Key Week 52 endpoints included Investigator's Global Assessment (IGA) 0/1 with at least a 2-grade improvement, Eczema Area and Severity Index 75 (EASI-75), and Worst Itch Numeric Rating Scale (WI-NRS) response. RESULTS: Of 336 randomized patients, 258 completed 52 weeks of treatment. Among patients initially randomized to ivarmacitinib, Week 52 IGA responses were achieved by 42.3% and 40.2% of patients in the 4 mg and 8 mg groups, respectively. EASI-75 responses were achieved by 60.6% and 55.9%, and WI-NRS responses by 59.6% and 45.1%, respectively. During the active-treatment period, treatment-emergent adverse events (TEAEs) occurred in 87.5% and 85.5% of patients in the 4 mg and 8 mg groups, respectively. The most frequent TEAEs were upper respiratory tract infection, COVID-19, SARS-CoV-2 test positive, and increased blood creatine phosphokinase. Serious TEAEs occurred in 5.6% and 4.4% of patients, respectively. CONCLUSION: Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo-controlled period. Because the extension phase had no placebo control after Week 16, long-term efficacy findings should be interpreted as descriptive. Atopic dermatitis (AD), also called atopic eczema, is a long‐lasting skin condition that causes red, itchy, and inflamed skin. It is common, affecting up to 1 in 5 children and about 1 in 10 adults worldwide. In people with moderate‐to‐severe AD, creams and ointments alone may not provide enough relief, and the condition can greatly affect sleep, mood, and quality of life. This study evaluated ivarmacitinib, a once‐daily oral treatment that blocks JAK1, a protein involved in inflammation. Earlier research showed that ivarmacitinib improved AD symptoms after 16 weeks of treatment. This study followed patients for up to 52 weeks to assess whether these benefits were maintained and to evaluate safety over time. A total of 336 patients aged 12–75 years with moderate‐to‐severe AD were enrolled at hospitals in China and Canada. Participants were randomly assigned to receive ivarmacitinib 4 mg, ivarmacitinib 8 mg, or placebo for 16 weeks. After Week 16, patients who had received placebo and continued in the study switched to ivarmacitinib, and patients initially assigned to ivarmacitinib continued their assigned treatment through Week 52. At Week 52, about 4 to 6 in 10 patients who started ivarmacitinib at the beginning of the study had marked improvement in skin symptoms and itch. Improvements were observed early and were generally maintained through Week 52. The safety profile over 52 weeks was generally consistent with that seen during the first 16 weeks, and most side effects were mild or moderate. The most common side effects were upper respiratory tract infection, COVID‐19, positive SARS‐CoV‐2 test results, and increased blood creatine phosphokinase, a muscle enzyme. These results provide longer‐term evidence for ivarmacitinib in adolescents and adults with moderate‐to‐severe AD, although the 52‐week findings should be interpreted with caution because there was no placebo group after Week 16.
引用
- Zhao Y, Gooderham M, Yang B, et al. 52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial. J Eur Acad Dermatol Venereol. 2026. PMID: 42683746. doi:10.1111/jdv.70710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。